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Feline injection site sarcoma (FISS) is an uncommon but important tumour in cats due 4	
to its locally aggressive biologic behaviour, poor prognosis and that it is linked to 5	
routinely administered vaccinations, which raises ethical questions regarding vaccine 6	
practices. Post vaccinal granulomas are a common occurrence in cats therefore client 7	
education is vital and careful monitoring should be adopted. Incisional biopsy is 8	
recommended to confirm diagnosis of FISS and full staging is recommended prior to 9	
determination of a treatment strategy. Tumour palpation has been shown to vastly 10	
underestimate the extent of tumour infiltration and therefore prospective treatment 11	
planning with advanced imaging is highly recommended. Although further studies are 12	
required to determine the most effective combination of treatment modalities for 13	
definitive treatment, a multi-modal approach is often required, based on expeditious 14	
and aggressive surgery in combination with radiotherapy +/- chemotherapy. 15	
Importantly early detection by careful post vaccination monitoring as well as a shift in 16	
vaccination practices is key to improving the outcome of FISS. 17	
 18	
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In 1991, a letter to the editor of the Journal of the American Veterinary Medical 2	
Association, written by Dr Hendrick and Dr Goldschmidt (Hendrick & Goldschmidt 3	
1991), highlighted an increasing concern relating to a link between cat vaccination 4	
and the development of soft tissue sarcomas. Further studies supporting these claims 5	
were quick to follow; the debate within the veterinary community about this issue 6	
continues today and it remains a viable concern for both the veterinary industry and 7	
pet owners alike. While it is now suspected that feline injection site sarcoma (FISS), 8	
originally known as vaccine site-associated sarcomas, may be linked to other 9	
iatrogenic inflammatory insults such as insulin, antibiotics and steroid injections, 10	
(Kass et al 2003), feline leukaemia and rabies vaccinations have the strongest 11	
epidemiological link (Kass et al. 1993; Hendrick & Goldschmidt 1991; Coyne et al. 12	
1997). 13	
The true incidence and prevalence of this worldwide issue is likely an under-14	
estimate due to under-reporting, however research has demonstrated that the 15	
incidence of sarcoma development as a result of vaccination in the United States is 16	
between 0.63-10 in every 10,000 vaccinated cats, depending on the study consulted 17	
and most commonly occurs after administration of rabies virus and FeLV (feline 18	
leukaemia virus) vaccines (Gobar & Kass 2002; Hendrick et al. 1994; Coyne et al. 19	
1997; Lester et al.).  Interestingly, in the United Kingdom, where the frequency of 20	
rabies vaccination is lower than in North America, the incidence is similar and is 21	
estimated to be between 1 in 16,000 and 1 in 50,000 cats (Dean et al. 2013).  22	
Veterinary surgeons have an ethical duty to protect our patients from disease. 23	
Our vaccine protocols have been developed to prevent easily acquirable, life limiting 24	
conditions, and as such, in the UK, the annual booster is often accepted as gold 25	
	 3	
standard practice. In human medicine, some might consider vaccine products that 1	
have cancer causing potential at this level of risk unacceptable. In response to this 2	
concern, the Vaccine-Associated Feline Sarcoma Task Force (VAFSTF) was created, 3	
and various clinical recommendations were developed. Many of these 4	
recommendations have been adopted in North America; yet, while guidance has been 5	
published, these recommendations have not generally been adopted as standard 6	
practice in the UK.  7	
In this article, the pathogenesis, case management and prognosis of FISS, 8	
including novel treatments and future directions, will be highlighted. Special 9	
emphasis on clinical work up and surgical planning is imperative in improving 10	
treatment outcome. Due to the considerable morbidity and expense involved in 11	
treatment coupled with the challenges associated with achieving long-term tumour 12	
control, prevention should focus on thoughtful vaccination protocols and adherence to 13	
VAFSTF recommendations.  14	
 15	
PATHOGENESIS 16	
In some species such as canines and humans, inflammatory associated sarcomas occur 17	
at very low rates; indeed the reported incidence of this disease in cats was also low 18	
prior to the 1980’s, at which time killed adjuvanted feline vaccines were marketed. 19	
Shortly after this time the pathology department at the School of Veterinary Medicine 20	
at Pennsylvania University identified an increase in inflammatory injection site 21	
reactions in feline biopsy specimens (Hendrick & Dunagan 1991). FISS manifests 22	
most commonly in cats as fibrosarcoma histologically, although, chrondrosarcoma, 23	
malignant fibrous histiocytoma and rhabdomyosarcoma have also been reported 24	
(Hendrick & Brooks 1994). Tumours appear to originate from proliferating fibroblasts 25	
	 4	
and myofibroblasts (Hendricks and Brooks, 1994). This may be a reflection of the 1	
differing feline fibroblastic response to injury relative to other species (Eggers Carroll 2	
et al. 2002). Localised vaccine reactions are common in cats vaccinated with rabies 3	
and feline leukemia virus vaccines, with one report suggesting that up to 80-100% of 4	
cats will have a reaction to rabies vaccination (Macy & Hendrick 1996; McEntee & 5	
Page 2001; Gobar & Kass 2002; Wilcock et al. 2012). In one study, it was found that 6	
2.7% of these post vaccinal nodules will result in malignant transformation over 7	
several months to years (Gobar & Kass 2002). It is not clear why some nodules 8	
become malignant while many others resolve, but it has been suggested that some cats 9	
may be genetically predisposed to neoplastic change (Hartmann et al. 2015). Ferrets 10	
have been reported to develop injection site sarcomas spontaneously while rodents 11	
can be experimentally induced to develop injection site sarcomas, suggesting this 12	
phenomenon is not unique to cats (Munday et al. 2003; Huggins & Grand 1963; 13	
Hendrick 2011).  14	
One theory in FISS formation is that in a genetically ‘tumour-susceptible’ cat, 15	
the chronic inflammatory stimuli provided by vaccine components leads to neoplastic 16	
transformation of these fibroblastic cells (Jelínek 2003; Eggers Carroll et al. 2002). 17	
Vaccine adjuvants such as aluminium have frequently been identified within these 18	
sarcomas on histological sections and ultra-structural studies and strengthen the 19	
suspicion of an injection-related tumour (Madewell et al. 2001; Hendrick et al. 1992). 20	
Although non-adjuvanted vaccines have been associated with FISS, adjuvanted 21	
vaccines, and particularly those containing aluminium products, are known to enhance 22	
localized inflammatory reactions and therefore are frequently highlighted as a risk 23	
factor for tumour development (Day et al. 2007). Further supporting the theory that 24	
injections or vaccines are involved is the fact that tumours occur most frequently in 25	
	 5	
the sub-cutis of vaccine injection sites. Historically, tumours were more likely to 1	
occur in the interscapular region, the most common site for injection, yet there has 2	
been a statistically significant shift in tumour location to regions corresponding to 3	
recommended vaccine sites in North America (Hendricks and Brooks, 1999, Shaw et 4	
al 2009).  To date, rabies and feline leukemia virus vaccines remain the injections 5	
most clearly associated with the development of FISS; it is estimated that the number 6	
of vaccines given simultaneously at the same location`n greatly increases the risk of 7	
FISS development (Kass et al. 1993).  8	
Precise mechanisms underlying tumour formation and progression in FISS are 9	
not known although several studies have attempted to elucidate some information 10	
regarding the molecular biology of these tumours. To date, researchers have 11	
investigated receptor and non-receptor protein tyrosine kinases that are involved in 12	
cell signalling, growth, differentiation and/or survival, p53 mutations that disrupt cell 13	
death pathways, and chromosomal aberrations that may influence tumour 14	
development and progression (Smith et al. 2009; Katayama et al. 2004; Lawrence et 15	
al. 2012; Nambiar et al. 2000; Hershey et al. 2005; Banerji & Kanjilal 2006; Banerji 16	
et al. 2007; Mayr et al. 1995; Petterino et al. 2006; Thomas et al. 2009). 17	
Understanding changes and alterations in tumour cells is important as it provides 18	
possible avenues for novel treatment approaches, 19	
PRESENTATION AND DIAGNOSTIC WORK UP 20	
FISS is most commonly identified at the site of previous vaccination and although 21	
there is a rapid rate of growth of this aggressive, locally invasive tumour, the lag time 22	
from vaccination to tumour formation can be variable. Compared to other non-23	
injection site related sarcomas, cats with FISS tend to be younger. Epidemiological 24	
	 6	
evidence points to two peak presentations; 6-7 years and 10-11 years (Kass et al. 1	
1993). Recognising that many cats will develop post vaccinal nodules at the site of 2	
injection, the VAFSTF established a protocol in 1999 leading to the creation of the 3-3	
2-1 rule (box 1). These guidelines recommend that any mass persisting for more than 4	
3 months after injection (vaccination), measuring more than 2 cm in diameter and 5	
increasing in size 1 month after injection should be biopsied (Morrison & Starr 2001).  6	
For any mass that occurs at an injection site associated with a vaccination, 7	
incisional biopsy is recommended for confirmation of diagnosis. As with other soft 8	
tissue sarcomas, a wedge, punch or needle biopsy should not extend into healthy 9	
tissue in order to avoid compromising future surgical or irradiated margins. Although 10	
fine needle aspiration cytology can be performed to rule out other causes of soft tissue 11	
masses such as mast cell tumour or abscess, biopsy is recommended where sarcoma is 12	
suspected due to the frequency of false negative results with fine needle aspirates 13	
(Morrison & Starr 2001; Wilcock et al. 2012). 14	
STAGING 15	
Once a histological diagnosis has been made from biopsy, thorough staging should be 16	
performed in order to identify the extent of disease and aid in determining treatment 17	
options. Staging should include urinalysis, FIV and FeLV testing, haematology and 18	
biochemistry profiles to rule out concurrent diseases that may affect treatment 19	
decisions. Three view inflated thoracic radiographs and/or computed tomography 20	
(CT) should be performed to identify potential metastatic disease. The pulmonary 21	
parenchyma is the most common metastatic site although other sites such as lymph 22	
node and abdominal viscera have been reported. The overall rate of metastasis in FISS 23	
is reported to be between 10 and 28% (Couto & Macy 1998; Hendrick et al. 1994; 24	
	 7	
Hershey et al. 2000; Romanelli et al. 2008), which is higher than in other feline soft 1	
tissue sarcomas. An early paper investigating positive prognostic factors for FISS 2	
indicated that the first surgical attempt was the most effective in terms of achieving 3	
long term control (Hershey et al. 2000). While this has not been well established in 4	
more recent studies, prospective treatment planning remains vital prior to determining 5	
a definitive approach to treatment. Advanced imaging with both pre and post contrast 6	
studies (CT or magnetic resonance imaging (MRI)) is strongly recommended prior to 7	
determining optimal treatment as it has been shown that palpation vastly 8	
underestimates the true extent of the tumour (Ferrari et al. 2015). CT in particular can 9	
be used for surgical or radiation therapy planning and can provide a reasonable 10	
estimate as to whether or not surgery alone is likely to be successful or if 11	
multimodality therapy is more appropriate (Figure 1). It is also important to recognize 12	
that microchips may be associated with imaging artefact, particularly on MRI thus 13	
knowledge about the presence and location of a microchip is beneficial (SAITO et al. 14	
2010). 15	
TREATMENT AND PROGNOSIS 16	
Prior to commencing treatment, as per the VASFSTF guidelines, it would be 17	
advisable to consult a veterinary oncologist for advice on the most up to date 18	
treatment recommendations based on the current literature (Box 2). Additionally, it 19	
has been demonstrated that there is a significant improvement in disease-free interval 20	
(DFI) when a complete first excision is performed at a referral institution compared to 21	
excision with a referring veterinary surgeon (274 days versus 66 days) (Hershey et al. 22	
2000). 23	
FISS should be treated both promptly and aggressively for the best long-term 24	
	 8	
outcome. Wide, en-bloc surgical excision, with a margin of 5cm of macroscopically 1	
healthy tissue and two fascial planes deep which therefore may include partial 2	
scapulectomy, hemipelvectomy or osteotomy of spinous processes, is the surgical 3	
treatment of choice (Phelps et al. 2011). Histopathologic assessment is important to 4	
confirm the diagnosis of FISS and to assess the margins; clean surgical margins do 5	
not guarantee long-term survival and approximately 20-30% of tumours that are 6	
cleanly excised will have recurrence (Romanelli et al. 2008; Cronin et al. 1998; 7	
McEntee & Page 2001; Phelps et al. 2011; Kobayashi et al. 2002). However, it is 8	
likely that surgical success rate is improved if complete radical surgical excision is 9	
achieved at the first surgery whereas recurrence is higher if clean margins are not 10	
achieved (Giudice et al. 2010). Notably, following wide en bloc excision, a recurrence 11	
rate of 14% was documented in a series of cats (Phelps et al. 2011), although this may 12	
reflect a number of temporal changes, such as surgical dose, surgeon experience, 13	
initial size of the tumour at diagnosis, and histopathology evaluation. Current 14	
vaccination guidelines stress the importance of vaccinating as distally as possible on a 15	
limb (below the elbow or stifle) or tail so that if a tumour develops, high amputation, 16	
potentially involving scapular or femoral disarticulation may have a higher likelihood 17	
of achieving complete margins (Hartmann et al. 2015; Shaw et al. 2009). While 18	
radical surgery is currently pursued by many veterinary oncologic surgeons, smaller, 19	
more conservative surgeries are frequently performed. The optimal surgical approach 20	
will vary with each patient and concise guidelines for all cats are not currently 21	
available. Less is known about more conservative approaches, as there has been a 22	
strong desire to achieve complete margins on histopathology. Additional knowledge 23	
of outcome and surgical dose and approach is still being garnered and may contribute 24	
to future recommendations regarding treatment. 25	
	 9	
Whilst surgery alone for some tumours may provide long term control, the 1	
majority of FISS occurring in the interscapular region are difficult to control with 2	
surgery alone and many require a combination of radiation therapy and surgery to 3	
decrease the incidence and time to recurrence (Kobayashi et al. 2002; Cronin et al. 4	
1998; Eckstein et al. 2009). Prospective treatment planning is vital and typically 5	
involves an oncologist, radiation oncologist and surgeon. Radiation therapy can be 6	
prescribed preoperatively or postoperatively, depending on the clinical scenario and 7	
planned approach. Preoperative radiation therapy attempts to sterilise the margins of 8	
bulky disease in order to decrease the likelihood of tumour recurrence. The benefit of 9	
preoperative approaches is that a smaller treatment field is typically treated and a 10	
lower overall dose can be utilised, thus may be more tolerable for the cat (Figure 2). 11	
Alternatively, postoperative radiation therapy attempts to kill residual tumour cells 12	
following surgery but typically requires that a larger volume of normal tissue is 13	
included in the irradiated field to a higher overall dose. Both preoperative and 14	
postoperative radiation therapy are associated with similar outcomes and delay the 15	
time to tumour recurrence (Eckstein et al. 2009; Cronin et al. 1998; Romanelli et al. 16	
2008; Bregazzi et al. 2001; Kobayashi et al. 2002). Currently there is insufficient 17	
evidence in the literature to assess the role of adjunctive chemotherapy in definitive 18	
treatment, however chemotherapy (often anthracycline-based) is currently considered 19	
to be potentially useful when postoperative radiation therapy is not available (Poirier 20	
et al. 2002; Bray & Polton 2014). More advanced radiation therapy equipment and 21	
planning software that allow for intensity modulated radiation therapy (IMRT) or 22	
stereotactic radiation therapy (SRT) may improve the ability of radiation to target 23	
tumour volumes while sparing normal tissue, thus placing more importance on the 24	
role of radiation in cats with tumours not amenable to surgery alone (Nolan et al. 25	
	 10	
2013). 1	
A number of palliative options exist for cats with advanced injection site 2	
sarcomas where definitive treatment is not possible. Chemotherapy or palliative 3	
radiation therapy can be used as single modalities or as part of a multimodality 4	
approach. Chemotherapy drugs (Barber et al. 2014; Poirier et al. 2002; Saba et al. 5	
2012; Kobayashi et al. 2002) such as doxorubicin alone or in combination with 6	
cyclophosphamide and CCNU have shown responses in the gross disease setting 7	
although other drugs may be tried as well given the undefined role of chemotherapy. 8	
Palliative intent radiation therapy, in which large doses of radiation are used 9	
infrequently, may improve quality of life and offer temporary tumour control in many 10	
cases (Nolan et al. 2013; Eckstein et al. 2009). Medical management with analgesia is 11	
also important as tumours can cause significant pain as they grow and invade normal 12	
structures. 13	
NOVEL THERAPIES 14	
As many injection site sarcomas recur in cats despite multimodality approaches, it is 15	
clear that novel treatment options are needed. FISS has been shown to express a 16	
number of dysregulated growth factor receptors, including the tyrosine kinase 17	
receptor platelet derived growth factor receptor (PDGFR), making this an attractive 18	
target. Initial in-vivo preclinical work investigating imatinib and masitinib 19	
demonstrate inhibition of PDGFR signalling, have shown some beneficial effects but 20	
require additional investigation to validate their clinical benefit and to determine their 21	
role in definitive management (Katayama et al. 2004; Lawrence et al. 2012; Turek et 22	
al. 2014; Holtermann et al. 2016). 23	
There is interest in the use of immunotherapy following approval of a 24	
	 11	
recombinant feline IL-2 vaccine in Europe (conditional licensure in the USA) for the 1	
treatment of FISS in conjunction with surgery and radiation therapy (Jas et al. 2015; 2	
Jahnke et al. 2007; Quintin-Colonna et al. 1996). IL-2 is a cytokine known to 3	
stimulate an anti-tumour immune response and it is thought that it may upregulate 4	
cytotoxic T lymphocyte and natural killer (NK) cell activity. Preliminary work with 5	
the vaccine suggested that cats treated with recombinant feline IL-2 in conjunction 6	
with surgery and brachytherapy had longer median time to recurrence compared to 7	
cats treated with local therapy alone, however additional work should evaluate its 8	
utility when conventional external beam radiation therapy is utilised (Jas et al. 2015).  9	
As the recombinant feline IL-2 vaccine is administered intra-tumourally or via 10	
subcutaneous injection at the surgery site, there is theoretical concern regarding the 11	
use of an injection that induces inflammation in an ‘FISS disposed’ cat; further 12	
studies will hopefully alleviate these concerns. 	13	
PREVENTION 14	
While novel treatments are needed to improve long-term control of FISS, the most 15	
important factor to decrease the impact FISS has on cats is prevention. In response to 16	
the concern over the link between vaccination and FISS, several strong 17	
recommendations have been published regarding frequency and site of vaccination in 18	
cats (box 3). The World Small Animal Veterinary Association (WSAVA) and the 19	
American Association of Feline Practitioners (AAFP) recommend vaccination of 20	
feline herpes virus (FHV), feline calicivirus (FCV) and feline panleukopenia virus 21	
(FPV) at an interval of 3 years and vaccination against feline leukaemia virus (FeLV) 22	
at a yearly interval only if that particular cat is at risk on contracting FeLV (Day et al. 23	
2010; Richards et al. 2006). Therefore an indoor cat with a very low chance of 24	
	 12	
exposure to FeLV does not require or benefit from this vaccine. The European 1	
Advisory Board on Cat Diseases (ABCD) advises FeLV vaccination every 2-3 years 2	
in cats over 3-4 years old.  Guidelines published by the ABCD and the AAFP 3	
recommend rabies vaccination in the right hindlimb and FeLV in the left hindlimb 4	
while all other vaccinations should be given in the right foreleg; vaccinations should 5	
be administered distal to the elbows and stifles (Hartmann et al. 2015; Richards et al. 6	
2006) (Figure 3). Of particular importance, all guidelines recommend avoidance of 7	
the interscapular region of any injections. To date, vaccinations are still recommended 8	
while considering the risk of disease in each cat although one may muse that 9	
discontinuing vaccinations may be the most effective means of prevention. 10	
To assess the effectiveness of this guidance, a study within the USA 11	
comparing vaccine location and incidence of FISS, before and after the VAFSTF 12	
guidance was published in 1996. Results were encouraging despite the fact that the 13	
highest incidence of FISS remained in the interscapular region, as there was a 14	
significant decrease in the incidence of interscapular FISS from 53% to 40% and a 15	
significant increase in the incidence of FISS in the right thoracic limb from 1% to 16	
10% (Shaw et al. 2009), indicating a shift in vaccine practices. A study by Dean et al 17	
(2012)  evaluated vaccine protocols used by UK veterinarians and found that despite 18	
published guidelines, most UK practices vaccinate for FHV, FPV, FCV and FeLV 19	
annually, most commonly in the interscapular region. Although distal limb can be a 20	
difficult site to vaccinate, a recent study suggested that cats not only tolerate 21	
vaccination in both locations, but also that the tail may represent an alternative site to 22	
the distal limb (Hendricks et al. 2014). 23	
In addition to adherence to vaccine locations, efforts should be made to 24	
	 13	
facilitate early detection and reduce inflammation at the injection site. All clients 1	
should be educated at the time of vaccination on post vaccinal nodules and how to 2	
monitor the injection site. Intramuscular vaccination should be avoided if possible, as 3	
tumours that develop within muscle are more difficult to detect. Administration of a 4	
cold vaccine has been associated with higher risk of FISS (Kass et al. 2003), 5	
therefore, while vaccines need to be kept refrigerated to maintain efficacy, 6	
consideration should be given to taking feline vaccines out of the fridge 15 minutes 7	
before administration. (Hartmann et al. 2015). Finally, although any vaccine can 8	
induce inflammation that may led to malignant transformation, non-adjuvanted 9	
vaccines, modified-live or recombinant vaccines, and/or those vaccines that provide 10	
prolonged immunity should be preferred over adjuvanted, killed, or short-acting 11	
vaccines. In an effort to reduce the number of vaccinations each cat receives in its 12	
lifetime, there is an argument to consider antibody titre measurement in order to 13	
assess the immune status of each individual cat prior to vaccination but this is not 14	
currently considered standard practice.  15	
CONCLUSIONS 16	
It is now known that vaccination of cats, once thought to be associated with little or 17	
no risk, is not without significant risk. Development of invasive injection-site 18	
sarcomas is arguably the most serious of the reported adverse reactions in cats, despite 19	
its relatively low incidence. While we as veterinarians and veterinary nurses must 20	
continue to protect cats against life limiting, preventable conditions with vaccination, 21	
the vaccination protocol for each individual patient should be carefully thought 22	
through from a holistic viewpoint, rather than a routine procedure. Administration of 23	
any irritant injection such as a vaccination or other injectable substance should be 24	
performed only if deemed necessary and as infrequently as possible, seeking oral 25	
	 14	
alternatives where available. When vaccines or other injections are administered, the 1	
interscapular area should be avoided. It appears that there may be resistance to 2	
published vaccine guidelines in the UK but it is unclear if this observation is uniform 3	
across the UK, if it is due to lack of awareness of these guidelines or if  the guidelines 4	
are viewed as impractical.  5	
There is an array of vaccination recommendations available to practitioners, 6	
not limited to the originally published VAFSTS guidelines. These include those by 7	
the World Small Animal Veterinary Association (WSAVA), the American 8	
Association of Feline Practitioners (AAFP), the European Advisory Board on Cat 9	
Diseases (ABCD), in addition to the vaccine manufacturer’s datasheets published in 10	
the National Office of Animal Health compendium  (NOAH, 2016). These guidelines 11	
all differ slightly from each other and as yet there is no cohesive conclusions or 12	
standardized approach regarding frequency, type and location of vaccination. For 13	
example, the AAFP recommend that FeLV vaccination should be repeated at intervals 14	
depending on an individual cat’s risk (Richards et al. 2006). The WSAVA 15	
recommend this vaccination should be repeated not more than every three years but 16	
only if there is a sustained risk of exposure (Day et al. 2010), whilst the ABCD 17	
recommends that cats over the age 3-4 years, should be re-vaccinated at a 2-3 year 18	
interval (Dean et al. 2012; Hartmann et al. 2015). On the other hand, data sheet 19	
recommendations produced by vaccination manufacturers for the majority of FeLV 20	
vaccinations available in the UK (NOAH, 2016) advise yearly re-vaccination. A 21	
survey analysing vaccine practices by UK veterinarians (Dean et al. 2012) showed 22	
that 84% of practices routinely gave FeLV vaccination annually, 1% every 2 years 23	
and no practices reported that their standard policy was to repeat FeLV vaccination 24	
every three years. The remainder of the practices surveyed decided on vaccination 25	
	 15	
frequency on an individual cat basis. Arguably, practitioners may be more inclined to 1	
follow manufacturer data sheet recommendations rather than other guidelines, 2	
particularly as these guidelines do not have unified conclusions and therefore perhaps 3	
come across as confusing.		Gentle reminders to carry out thoughtful vaccination 4	
practices that include routine monitoring of post vaccinal nodules, as well as to 5	
intervene and consider referral early may help reduce the impact that injection site 6	
sarcomas have on cats in the UK.	7	
 8	
KEY POINTS 9	
1. Vaccine practices with specific attention to the location and frequency of 10	
vaccines should be carefully considered and protocols determined based on the 11	
cat’s individual risk.  12	
2. Careful monitoring of vaccination sites and client education should be 13	
routinely performed in practice.  14	
3. Early intervention and adequate local control of the disease is important to 15	
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FIGURE	LEGENDS	1	
Figure	1:	CT	images	illustrating	the	infiltrative	nature	of	injection	site	sarcoma.	2	
(A)	represents	a	rapidly	growing,	deeply	invasive	sarcoma	that	developed	in	the	3	
interscapular	region.	Note	the	proximity	to	critical	structures	such	as	the	heart	4	
and	lung.		(B)	represents	a	tumour	located	on	the	proximal	hindlimb	but	due	to	5	
its	size	and	proximal	location,	amputation	without	hemipelvectomy	would	not	6	
achieve	good	control.		7	
	8	
Figure	2:	Sagittal	(A)	and	axial	(B)	CT	images	used	for	radiation	treatment	9	
planning	with	dose	colour	wash	displayed.	Radiation	dose	is	represented	by	10	
various	colours	with	red	indicating	the	prescribed	dose	of	radiation,	with	a	11	
transition	to	yellow,	green	and	blue	as	radiation	dose	diminishes.	Note	the	12	
excessively	large	size	of	the	infiltrative	tumour	and	the	normal	structures	(spinal	13	
cord,	lungs)	that	are	irradiated	due	to	their	proximity	to	the	tumour	volume.	Cats	14	
with	extensive	disease	such	as	this	may	benefit	from	preoperative	radiation	15	
therapy	in	order	to	reduce	the	overall	radiation	dose	to	normal	tissues.	16	
	17	
Figure	3:	Recommended	vaccination	locations	for	common	feline	vaccines	based	18	
on	AAFP	and	ABCD	guidelines.		19	
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